雲頂新耀-B(01952.HK)合作伙伴Spero與輝瑞公司就SPR206達成區域授權許可協議
格隆匯7月5日丨雲頂新耀-B(01952.HK)公佈,公司合作伙伴Spero Therapeutics, Inc. (Nasdaq:SPRO)("Spero")與輝瑞公司(NYSE:PFE)("輝瑞")簽訂了SPR206的區域授權許可協議("輝瑞授權許可協議")。SPR206是Spero的靜脈注射用新一代多黏菌素候選藥物,正在開發用於治療醫院環境下多重耐藥革蘭氏陰性菌重症感染。
根據輝瑞授權許可協議的條款,Spero已授予輝瑞美國和亞洲地區以外地區開發、製造和商業化SPR206的權利。作為交換,Spero有資格獲得8000萬美元的開發和銷售里程碑付款,以及SPR206在這些區域的淨銷售額的高個位數到低兩位數的特許權使用費。Spero還獲得輝瑞4000萬美元股權投資,作為輝瑞突破性增長計劃的一部分,該計劃專注於資助創新科學以滿足患者的需求。
根據公司與Spero於2019年1月公佈及於2021年1月修訂的授權許可協議,公司擁有在大中華區、韓國和部分東南亞國家開發、製造和商業化SPR206用於治療多重耐藥革蘭氏陰性細菌感染的獨家權益,該協議於2021年1月就將上述區域SPR206的相關專利權轉讓給公司予以修訂。輝瑞授權許可協議不會影響公司對SPR206的權益。
據悉,SPR206是一種潛在的同類領先的新型多黏菌素類抗生素,旨在減少目前臨牀上多黏菌素B和黏菌素治療時產生的腎臟毒性。多黏菌素常被用作對抗多重耐藥革蘭氏陰性菌感染的最後手段,但它們在臨牀使用時與明顯的神經毒性和腎毒性有關。Spero在健康志願者中進行的雙盲、安慰劑對照1期臨牀試驗中,在針對目標多重耐藥革蘭氏陰性細菌感染的可能治療範圍內,SPR206表現出良好的耐受性,更重要的是,在研究的劑量範圍內也沒有顯示腎毒性的證據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.